Tag
This phase 2 trial assessed SAR443820, a RIPK1 inhibitor, in ALS patients; it showed no clinical efficacy and increased hepatic side effects, indicating limited therapeutic potential in ALS.
The integrated analysis of the VALOR trial and its open-label extension reveals that early initiation of tofersen significantly slows functional decline, preserves respiratory capacity, and improves survival in patients with SOD1-ALS over a
A large retrospective cohort study reveals a transient association between traumatic brain injury (TBI) and elevated amyotrophic lateral sclerosis (ALS) risk, suggesting early ALS symptoms may predispose to injury rather than TBI causing AL
